PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 26, 2026ACS Synthetic Biology0 citations

Receptor-Guided AAV Tropism Engineering via MATCH

View Full Paper
NGNolan GrahamSKSatheesh KumarJRJoseph Rainaldi

Key Points

  • To develop a method for precise control over the tropism of adeno-associated viruses (AAVs) for gene therapy applications.
  • Implemented MATCH technology for receptor-guided retargeting of AAVs through conjugation to targeting proteins.
  • Used mosaic AAV capsids with SpyTag incorporation for controlled protein attachment.
  • Established a 'Mix-and-MATCH' strategy for coexpressing capsids and targeting ligands during vector production.
  • MATCH-AAVs with anti-CD3 antibodies achieved ∼58% transduction of human T cells in vitro.
  • TfR1-targeted MATCH-AAV9 showed up to an 88-fold increase in brain expression compared to wild-type AAV9 in vivo.
  • TfR1-targeted vectors enabled extensive transduction of brain tissue, demonstrating effective blood-brain barrier crossing.

Abstract

Precise control over viral tropism remains a major challenge in the development of gene delivery technologies. We present MATCH (Modulation of AAV Tropism through Conjugation to Homing proteins), a modular biochemical method that enables programmable, receptor-guided retargeting of adeno-associated viruses (AAVs) through site-specific covalent protein conjugation. By incorporating a SpyTag peptide motif into selected AAV capsid loops, MATCH allows one-step, stoichiometrically defined attachment of recombinant SpyCatcher-linked targeting proteins to the viral surface. Using mosaic AAV-DJ and AAV9 capsids with controlled SpyTag incorporation, we achieve efficient assembly and tunable ligand display. MATCH-AAVs conjugated to an anti-CD3 single-chain antibody efficiently activate and transduce resting human T cells within mixed PBMC populations in vitro, achieving transduction levels of up to ∼58% of the total PBMCs. Conjugation to transferrin receptor (TfR1)-binding proteins yielded enhanced brain transduction in vivo, with murine TfR1-targeted MATCH-AAV9 exhibiting up to an 88-fold increase in brain expression relative to wild-type AAV9. Human TfR1-targeted vectors similarly enabled robust, receptor-dependent transduction both in vitro and in humanized mouse models. Both TfR1-targeted vectors enabled widespread transduction of the parenchyma, consistent with TfR1-mediated crossing of the blood-brain barrier. Finally, we establish a streamlined one-pot "Mix-and-MATCH" production strategy in which capsid and targeting ligands are coexpressed during vector generation, yielding functional, targeted AAVs at titers comparable to conventional production. This simple and generalizable synthetic-biology approach provides a versatile toolkit for rational AAV tropism engineering, offering a scalable route to custom vector design for research and therapeutic applications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Graham et al. (2026) studied this question.

synapsesocial.com/papers/6a1538ebb5d9c58d83e8c8cahttps://doi.org/10.1021/acssynbio.5c00910
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid2012 · 142 citations
  2. 2Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals2024 · 8 citations
  3. 3Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma2017 · 271 citations
  4. 4Degradation of T Cell Receptor (TCR)–CD3-ζ Complexes after Antigenic Stimulation1997 · 329 citations
  5. 5New Insights into How Trafficking Regulates T Cell Receptor Signaling2016 · 14 citations